Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q5XG87
UPID:
PAPD7_HUMAN
Alternative names:
DNA polymerase sigma; LAK-1; Non-canonical poly(A) RNA polymerase PAPD7; PAP-associated domain-containing protein 7; TRAMP-like complex polyadenylate polymerase; Terminal guanylyltransferase; Terminal uridylyltransferase 5; Topoisomerase-related function protein 4-1
Alternative UPACC:
Q5XG87; A0A0X1KG68; A8K1E2; M1JCE6; O43289; Q17RZ1; Q9Y6C1
Background:
Terminal nucleotidyltransferase 4A, known by alternative names such as DNA polymerase sigma and Non-canonical poly(A) RNA polymerase PAPD7, plays a crucial role in RNA processing. It catalyzes the transfer of ATP and GTP on RNA 3' poly(A) tail, leading to mRNA stabilization and protection from deadenylation. This enzyme is a key component of a TRAMP-like complex, contributing to post-transcriptional quality control by polyadenylating nuclear RNA substrates for exosome degradation.
Therapeutic significance:
Understanding the role of Terminal nucleotidyltransferase 4A could open doors to potential therapeutic strategies.